Skip to main content
NCBI home page
ACS Medicinal Chemistry Letters logoLink to ACS Medicinal Chemistry Letters
. 2018 Oct 31;9(12):1223–1229. doi: 10.1021/acsmedchemlett.8b00380

Design, Synthesis, and Characterization of a Fluorescence Polarization Pan-BET Bromodomain Probe

Carolyn N Paulson †, Xianghong Guan †, Alex M Ayoub ‡, Alice Chan §,∥, Rezaul M Karim §,∥, William C K Pomerantz ‡, Ernst Schönbrunn §,∥, Gunda I Georg †,*, Jon E Hawkinson †,*
PMCID: PMC6295860  PMID: 30613330

Abstract

graphic file with name ml-2018-003807_0007.jpg

Several chemical probes have been developed for use in fluorescence polarization screening assays to aid in drug discovery for the bromodomain and extra-terminal domain (BET) proteins. However, few of those have been characterized in the literature. We have designed, synthesized, and thoroughly characterized a novel fluorescence polarization pan-BET chemical probe suitable for high-throughput screening, structure–activity relationships, and hit-to-lead potency and selectivity assays to identify and characterize BET bromodomain inhibitors.

Keywords: bromodomain and extra-terminal domain, BET, pan-BET probe, fluorescence polarization

Bromodomain (BRD)-containing proteins are highly conserved epigenetic regulators that recognize and bind to acetylated lysine (KAc) residues of histones. BRDs recruit proteins to macromolecular complexes essential for chromatin remodeling and transcriptional control.1 The highly diverse BRD family members share a conserved structural motif comprised of a left-handed bundle of four alpha helices (αZ, αA, αB, αC) that are linked by two variable loop regions (ZA and BC loops) flanking a deep central hydrophobic cavity that recognizes sequences containing ε-N-acetylated lysine residues.2 Each of the BRD and extra-terminal domain (BET) family members, BRD2, BRD3, BRD4, and BRDT, contain two N- and C-terminal KAc binding domains (designated as BD1 and BD2, respectively), which play important roles in regulating the transcription of growth-promoting genes and cell cycle regulators.3 While BRD2, 3, and 4 are ubiquitously expressed, BRDT is exclusively found in the testis.4 Mutagenesis studies have shown that loss of BRDT-BD1 (BRDT-1) results in abnormal spermatids and complete sterility in mice5 making BRDT-1 an attractive target for developing nonhormonal male contraceptives.6 The greatest challenge for BRD drug discovery efforts is identifying compounds that are selective for individual BRD proteins due to the high homology of KAc binding sites within BRD families.7 In addition, the discovery of potent inhibitors with high selectivity for BD1 over BD2 (or BD2 over BD1) has been challenging because, although the BET BRD loop regions are variable, the BD1 and BD2 substrate binding pockets show high sequence similarity.7

Several chemical probes for use in fluorescence polarization (FP) assays have been developed to aid in drug discovery programs for BET proteins. Previously reported probes for BET BRDs either have low binding affinities or have low polarization signal windows, and most of them are not well characterized. For example, BODIPY-conjugated BI6727 (BI-BODIPY) is reported to have a KD of 50–110 nM for BRD4-BD1 (BRD4-1)8,9 and only a 40 mA polarization signal window, while the Alexafluor488-IBET10 and FITC-JQ111−13 probes remain uncharacterized. This prompted us to develop a novel FP small molecule chemical probe utilizing the high affinity pan-BET inhibitor SG3-179 (Figures 1 and 3; compound 5 in Ember et al.14). SG3-179–BODIPY probe 16 was selected for further characterization as described below.

Figure 1.

Figure 1

Open in a new tab

Molecular docking predicts that compound 16 will maintain high affinity for BRDT-1. Compound 16 orients similarly to the parent compound SG3-179 and maintains the key interaction with Asn109 of BRDT-1 (PDB: 4FLP). The fluorophore is solvent exposed without the possibility of any steric hindrance with the protein.

Figure 3.

Figure 3

Open in a new tab

Structures of the 10 reference BET inhibitors with diverse chemical scaffolds selected to validate the FP assay. CAS 2096312-12-8 refers to compound 3s from Ayoub et al.9

A general challenge for probe development is to avoid a significant loss of binding affinity caused by steric hindrance of the attached fluorescent label. To achieve this goal, we docked SG3-179 to a representative BET-family protein BRDT-1 (PDB: 4FLP) to reveal the binding mode of SG3-179 for BRDT-1 (Figure 1). The predicted binding mode is similar to the later released crystal structure SG3-179 in complex with BRD4-1 (PDB: 5F63).14 The diaminopyrimidine core of SG3-179 forms a direct hydrogen bond with Asn 109 in the KAc binding site of BRDT-1, and the water exposed piperidine moiety is far away from this key interaction, which therefore provided a reasonable position to connect to a fluorophore. We chose BODIPY as the fluorophore due to its long fluorescence lifetime (5–6 ns)15 and because tetra-methyl BODIPY is an inexpensive fluorophore among BODIPY dyes and numerous chemistries involving tetra-methyl BODIPY are available for rapid linker incorporation.16−18 Although a longer linker length may alleviate steric hindrance, local motion of fluorophores attached by flexible linkers can decrease the polarization of the bound probe (“propeller effect”).19 In order to identify the optimal balance between steric hindrance and unrestrained fluorophore motion, linker length and flexibility were explored.

The synthetic route for SG3-179 based probes 16–18 is shown in Schemes 1 and 2. The synthesis of the KAc binding site ligand employed procedures similar to the methods reported for the preparation of SG3-179 (Scheme 1).20,21 Protection of commercially available 4-chloro-3-nitroaniline with Boc anhydride gave 1, followed by reduction of the nitro group with hydrazine to provide aniline 2. Reaction of 2 with tert-butylsulfinyl chloride furnished tert-butylsulfinyl 3 that was further oxidized with mCPBA to sulfonamide 4. Deprotection of 4 with TFA produced aniline 5, which was reacted with 2,4-dichloro-5-methylpyrimidine to afford chloropyrimidine 6. Intermediate 7 was obtained by coupling 4-amino-2-fluorobenzoic acid and tert-butyl 4-aminopiperidine-1-carboxylate, using 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate (HATU) in the presence of N,N-diisopropylethylamine (DIEPA) in dry DMF. Connection of fragments 6 and 7 by a Buchwald–Hartwig coupling reaction yielded 8, which was then Boc deprotected with TFA to give the KAc binding site ligand 9.

Scheme 1.

Scheme 1

Open in a new tab

Reagents: (a) (Boc)2O, THF, reflux, 28 h, 58%; (b) Pd/C, hydrazine monohydrate, MeOH, reflux, 10 h, 64%; (c) 2-methylpropane-2-sulfinic chloride, pyridine, DCM, rt, 20 h, 77%; (d) mCPBA, DCM, rt, overnight, 84%; (e) TFA, DCM, rt, 2 h, 78%; (f) 2,4-dichloro-5-methylpyrimidine, DIPEA, isopropanol, 120 °C, 2 d, 36%; (g) tert-butyl 4-aminopiperidine-1-carboxylate, HATU, DIPEA, DMF, rt, 12 h, 95%; (h) compound 6, Pd2(dba)3, (±)-2,2′-Bis(diphenylphosphino)-1,1′-binaphthalene (BINAP), NaOtBu, 1,4-dioxane, 110 °C, 5 h, 90%; (i) TFA, DCM, 12 h, 91%.

Scheme 2.

Scheme 2

Open in a new tab

Reagents: (a) DMF, POCl3, 0 °C, 2–3 h, then 50 °C, 3 h, 89%; (b) NaClO2, H2O, NaH2PO4, rt, 15 h, 30%; (c) malonic acid, pyridine, DMF, 90 °C, 5 h, 28%; (d) methyl acrylate, 20 mol % of Pd(OAc)2, tert-BuOOBz, DMSO, 35 °C, 5 d, 57%; (e) Pd/C, H2, MeCN, MeOH, rt, 12 h, 80%; (f) NaOH, DCM/MeOH/H2O, rt, 10 h, then neutralize, 98%; (g) intermediate 11, 12, or 15, HOBt, EDC, DIPEA, DCM, rt, 6 h, 72–93%.

The synthesis of the fluorophore moiety commenced with commercially available tetramethyl-BODIPY (Scheme 2) by reaction with DMF in the presence of POCl3 to produce aldehyde 10,17 which was then oxidized to carboxylic acid 11. Acrylic acid 12 was synthesized from aldehyde 10 by a Knoevenagel condensation.18 A Heck-type reaction between tetramethyl-BODIPY and methyl acrylate catalyzed by Pd(0) yielded methyl acrylate 13.16 The double bond in 13 was reduced with H2 to give methyl propionate 14, which was hydrolyzed to yield acid 15. Fluorophores 11, 12, and 15 were linked to ligand 9 (HOBt and EDC) to produce BODIPY based FP probes 16–18.

In comparison to compound 16, which has sharp UV absorption and fluorescence excitation and emission peaks similar to BODIPY, the peaks for compounds 17 and particularly 18 are broadened and red-shifted (Figure S1). Although it is not clear why compound 17 has a red-shifted emission spectrum, the extended π-conjugated system present in compound 18 is expected to produce a higher LUMO level and narrowed HOMO–LUMO gap,22 which likely explains the red-shifted emission spectrum.

The three probes (16–18) were then tested against BRDT-1 in a FP assay to assess probe affinity and signal window (Figure S2). Whereas probes 16 and 18 have similar affinities, probe 16 had the highest FP signal window (Bmax > 100 mP) at the standard BODIPY excitation and emission wavelengths and was therefore selected for further characterization. KD values for all the BET family proteins (BRDT-1, BRDT-2, BRDT-T, BRD2-1, BRD2-2, BRD3-1, BRD3-2, BRD4-1, BRD4-2, and BRD4-T, where -T designates the BD1 and BD2 tandem BRD protein), and two representative non-BET family proteins (BRD7 and BRD9) were determined with FP probe 16 (Table 1, Figures 2 and S3).

Table 1. Affinity of Pan-BET FP Probe 16 for BRD Proteinsa.

KD, nM
  BD1 BD2 tandem
BRDT 17 ± 2 10 ± 2 5.5 ± 0.6
BRD4 17 ± 1 9.6 ± 0.4 10 ± 1
BRD3 23 ± 1 7.5 ± 0.5  
BRD2 56 ± 4 12 ± 1  
BRD7 12 000 ± 2000    
BRD9 7600 ± 1300    
Open in a new tab
a

Values are mean + SEM in nM, where n ≥ 3 independent experiments.

Figure 2.

Figure 2

Open in a new tab

Pan-BET probe 16 binds with high affinity to BET BRDs, but only weakly to other BRD proteins. Error bars represent ± SEM where n ≥ 3.

FP probe 16 exhibited low nanomolar affinities for all of the BET family proteins (6–56 nM) but had KD values in the low micromolar range for the two non-BET family proteins (8–12 μM) (Figure 2). The lower affinity of probe 16 for BRD7 and BRD9 was expected based upon previously reported SG3-179 BROMOScan data.14 Therefore, compound 16 is a pan-BET probe but is unlikely to be a useful tool for non-BET BRDs. Probe 16 has a slight preference for BD2 over BD1 BRDs, ranging from 1.7- to 4.7-fold higher affinity for BD2 depending on the BET family member. In contrast to the BRD4-T protein, the pan-BET probe 16 bound BRDT-T with 2- to 3-fold higher affinity than the individual BRDT BRDs. Although it has been argued that the two BRDs of BRDT function independently due to the long flexible linker connecting them,23 the higher affinity of the probe for BRDT-T suggests that there may be cooperativity between the tandem BRDs or that the 123 aa linker may stabilize one or both BRDs.

Ten representative BET BRD inhibitors with varying scaffolds and selectivities were chosen for competition studies to establish that pan-BET probe 16 provides the expected affinity and selectivity values for the BET BRDs. The structures of the reference compounds SG3-179, ABBV-075, TG101209, (+)-JQ1, (−)-JQ1, CAS 2098312-12-8, bromosporine, BI2536, MS436, and RVX-208 are illustrated in Figure 3. IC50 values were generated for all ten compounds against the BET-family proteins, and Ki values were calculated using the equations of Nikolovska-Coleska et al.24 (Figures 4 and S4, Table 2). In some cases, Ki values could not be determined because IC50 values were too low relative to the protein concentration (30–130 nM) used in the assay. In these cases, the apparent IC50 values likely underestimate the true potency of the inhibitors. As protein concentrations could not be lowered in order to maintain a sufficient signal window, an alternate method must be employed to obtain accurate affinity estimates for these very potent inhibitors due to this “floor effect”. Additionally, Ki values are not reported for BRDT-T and BRD4-T as the Ki calculation equation cannot be used for proteins with >1 ligand binding site.24

Figure 4.

Figure 4

Open in a new tab

Competitive displacement of pan-BET probe 16 by 10 reference BET inhibitors at (a) BRDT-BD1 and (b) BRDT-BD2. Error bars represent ± SEM where n ≥ 3. Z′ value for BRDT-1 = 0.78 ± 0.04 (mean ± SEM).

Table 2. Inhibitory Potency (IC50) and Affinity (Ki) of Representative Inhibitors for BET Family BRDs Determined Using pan-BET FP Probe 16a.

compd   BRDT-1 BRD2-1 BRD3-1 BRD4-1 BRDT-2 BRD2-2 BRD3-2 BRD4-2 BRDT-T BRD4-T
SG3-179 IC50 140 ± 10 114 ± 1 200 ± 20 250 ± 16 237 ± 8 250 ± 25 90 ± 10 220 ± 20 307 ± 7 137 ± 7
Ki 15 ± 2 42 ± 1 20 ± 3 17 ± 1 50 ± 2 41 ± 6 6 ± 2 27 ± 341    
ABBV-075 IC50 12 ± 1 9.0 ± 0.5 17 ± 2 19 ± 2 11 ± 1 14.3 ± 0.6 7.7 ± 0.7 13 ± 1 32 ± 3 11.5 ± 0.3
(+)-JQ1 IC50 130 ± 10 60 ± 7 110 ± 10 120 ± 10 85 ± 7 110 ± 10 60 ± 7 97 ± 4 170 ± 12 70 ± 5
Ki 13 ± 2       15 ± 1 14 ± 2   8.6 ± 0.6    
CAS 2098312-12-8 IC50 380 ± 10 7.4 ± 0.2 21 ± 2 260 ± 10 130 ± 10 12.5 ± 0.9 8.3 ± 0.7 180 ± 16 120 ± 16 15 ± 1
Ki 60 ± 2     18 ± 2 27 ± 3     21 ± 3    
bromosporine IC50 390 ± 9 18 ± 2 43 ± 5 410 ± 40 1300 ± 300 52 ± 7 27 ± 2 700 ± 100 39 ± 1 8.5 ± 0.2
Ki 62 ± 2     35 ± 5 310 ± 40     90 ± 20    
BI2536 IC50 441 ± 7 9.0 ± 0.9 34 ± 2 240 ± 20 1050 ± 80 86 ± 7 25 ± 1 360 ± 10 68 ± 3 12.4 ± 0.7
Ki 71 ± 1     15 ± 2 250 ± 20 9.3 ± 1.3   49 ± 2    
TG101209 IC50 830 ± 60 1390 ± 40 1800 ± 100 1100 ± 90 2400 ± 100 3900 ± 200 1120 ± 10 2000 ± 80 2300 ± 100 740 ± 10
Ki 140 ± 10 700 ± 20 320 ± 20 120 ± 10 560 ± 30 760 ± 40 146 ± 1 300 ± 10    
MS436 IC50 2400 ± 100 620 ± 20 1300 ± 80 1200 ± 100 4700 ± 500 2700 ± 400 1550 ± 70 3400 ± 100 5700 ± 300 1200 ± 100
Ki 450 ± 20 300 ± 10 220 ± 20 130 ± 10 1200 ± 100 540 ± 80 205 ± 9 536 ± 5    
RVX-208 IC50 43000 ± 1600 13000 ± 600 43000 ± 3000 11000 ± 200 4800 ± 500 4000 ± 200 3300 ± 100 3000 ± 400 26000 ± 3000 9000 ± 1000
Ki 8200 ± 300 6700 ± 300 7800 ± 500 1300 ± 30 1200 ± 100 800 ± 50 450 ± 10 450 ± 60    
(−)-JQ1 IC50 >10 000 >10 000 >10 000 >10 000 >10 000 >10 000 >10 000 >10 000 >10 000 >10 000
Open in a new tab
a

Values are mean ± SEM in nM, where n ≥ 3. Ki values are included for BRDs containing a single binding domain (BD1 or BD2) if potency values are greater than the lower sensitivity limit of the assay (IC50 ≥ 1.5× BRD concentration).

Parent compound SG3-179 has been reported to have an IC50 ≈ 20 nM for both BRDT-1 and BRD4-1 using an AlphaScreen assay.14 SG3-179 FP Ki values are ∼15 nM for these BRDs. SG3-179 FP Ki values for BD1 domains of the four BET BRDs correlate well with the KD values obtained for the SG3-179-BODIPY probe 16. However, SG3-179 has 3- to 5-fold lower affinity for the BD2 domains of BRDT, BRD2, and BRD4 based on SG3-179 Ki values relative to probe 16KD values, perhaps due to a contribution of the fluorophore to the binding of probe 16 to these proteins.

ABBV-075, also known as mivebresib, is a potent small molecule BET inhibitor presently in a Phase I clinical trial for patients with advanced hematologic malignancies and solid tumors.25 ABBV-075 has previously been reported to be selective for tandem BRDT, BRD2, and BRD4 proteins (Ki = 1–2 nM) over the tandem BRD3 protein (Ki = 12.2 nM) in TR-FRET assays.25 When tested in the FP assay reported here, the IC50 values ranged from 9 to 32 nM for all of the BRD proteins. These IC50 values likely underestimate the true affinity of ABBV-075, and Ki values could not be calculated due to the “floor effect” described above, consistent with the high affinity values reported using the TR-FRET assay.25

The prototypic BET inhibitor, (+)-JQ1, is a thieno-triazolo-1,4-diazepine with reported AlphaScreen and TR-FRET IC50 values ranging from 18–91 nM for BRD4-1,14,26,29,30 14–33 nM for BRD4-2 and BRD3-1,29,30 and 100–150 nM for BRDT-1 and BRD2-1.14,26 The FP assay provides similar IC50 values, particularly for BRDT-1, although it indicates a higher potency of (+)-JQ1 for BRD2-1, but a lower potency at BRD3-1 and BRD4-1. (−)-JQ1, the inactive enantiomer of (+)-JQ1, is considerably less potent with reported IC50 values of 8354 and >10 000 nM for BRD4-1 and 52 120 nM for BRD4-2.29,30 We report similar findings in our FP assay in which (−)-JQ1 had IC50 values >10 000 nM for all BET BRDs.

The dihydropyridopyrimidine compound (CAS registry number: 2098312-12-8) is a potent BET inhibitor that has been shown to have submicromolar affinity (BRDT-1, Ki = 200 nM; BRD4-1, Ki = 110 nM) in a FP assay using BI-BODIPY.9 Three- to 6-fold higher affinity values were obtained using the SG3-179-BODIPY probe 16 for BRDT-1 and BRD4-1, respectively. The prior report by Ayoub et al.9 carried out the experiment at a 5-fold higher DMSO concentration (0.5% vs 0.1%), which is known to affect BRD binding interactions.28 Additionally, 2098312-12-8 had higher affinity for BD1 and BD2 of both BRD2 and BRD3, which exceeded the sensitivity found in the literature, KD values for bromosporine using ITC have been reported to be in the 40−100 nM range for BRDT-1 and for both BD1 and BD2 of BRD2, BRD3, and BRD4, whereas BRDT-2 had a significantly higher KD.

Bromosporine is a promiscuous BRD inhibitor that was developed to target the conserved KAc recognition site of BRD-containing proteins. While IC50 and Ki information could not be found in the literature, KD values for bromosporine against all of the BET proteins using ITC have been reported to be in the 40–100 nM range for BRD2, BRD3, BRD4, and BRDT, forms BD1 and BD2, excluding BRDT-2 which had a significantly higher KD value (KD = 172 nM).27 Similarly, Ki values obtained in the FP assay for BRD4-1, BRD4-2, and BRDT-1 ranged from 35–90 nM, and bromosporine had lower affinity for BRDT-2 (Ki = 310 nM). In contrast, bromosporine had higher affinities for BD1 and BD2 of both BRD2 and BRD3 in the FP assay that exceeded the sensitivity of the assay.

BI2536 is a potent and selective inhibitor of PLK1 (IC50 = 0.83 nM) and has antitumor activity against relapsed or refractory acute myeloid lymphoma (AML) and nonsmall cell lung cancer in phase I/II clinical trials. It binds to the KAc recognition site of BRD4 through an elaborate network of hydrogen bonding and van der Waals interactions.26 B12536 was shown to be selective for BRD4-1 over BRDT-1 with IC50 values of 25 and 260 nM, respectively, in an AlphaScreen assay.26 Similarly, in the FP assay, BI2536 had higher affinity for BRD4-1 (Ki = 15 nM) compared to BRDT-1 (Ki = 71 nM). We also found that BI2536 had high affinity for BRD2-2 (Ki = 9.3 nM).

TG101209, a dual BET BRD and JAK2 kinase inhibitor, has been reported in the literature to have lower affinity for BRD2-1 (IC50 = 680 nM) relative to BRD3-1, BRD4-1, and BRDT-1 (IC50 = 130–290 nM).26 The Ki values determined in the FP assay for these BRDs revealed a similar profile in which TG101209 was 2–5 times less active against BRD2-1 (Ki = 700 nM) than the other BRD BD1s (Ki = 120–320 nM).

The BD1-selective diazobenzene-based inhibitor MS436 has been reported to have a Ki < 85 nM for BRD4-1 and had >4-fold lower affinity for BD2.31 In our assay, MS436 showed similar activity with a BRD4-1 Ki of 130 nM and 4-fold lower affinity for BRD4-2. MS436 had ∼2- to 4-fold lower affinity for the other BET BRDs and showed lower selectivity for their BD2 domains.

RVX-208 has been evaluated in several clinical trials for the treatment of atherosclerosis and associated cardiovascular disease.32 RVX-208 has been reported to be a BD2-selective inhibitor of BET proteins with KD values measured by ITC for BD1 that are 8.5- to 23-fold higher than those determined for BD2, with highest selectivity for BRD2 and BRD3.32 In the FP assay, a similar trend was observed where RVX-208 is 3-17 times selective for BD2 over BD1 depending on the BRD protein, with highest BD2 selectivity in BRD3.

Several compounds, including SG3-179, ABBV-075, (+)-JQ1, TG101209, MS436, and RVX-208 inhibited the binding of the pan-BET probe 16 to the BRDT-T and BRD4-T proteins with IC50 values close to their respective BD1 and BD2 domains, as expected assuming no effect of the 123 aa linker on BRD affinity. In contrast, CAS 2098312-12-8, bromosporine, and BI2536 had considerably lower IC50 values for the tandem BRDT and BRD4 BRDs compared to the individual BD1 and BD2 domains, up to >80-fold higher potency for BRD4-T over BRD4-2 in the case of bromosporine. These latter inhibitors apparently bind to BRDs in the tandem protein in a cooperative manner or, alternatively, the amino acid linker in the tandem proteins induces conformational changes in the BD1 and/or BD2 domains that increase the affinity of these inhibitors, as observed for probe 16 at BRDT-T (Table 1).

In conclusion, the novel pan-BET probe 16 has high affinity for BD1, BD2, and tandem constructs of BET family members and provides a high FP signal window sufficiently robust for HTS (Z′ = 0.78, Figure 4). It can be used to establish the SAR for inhibitor series, determine the selectivity of inhibitors for BET family members and their respective BD1 and BD2 KAc recognition sites, and for HTS to identify novel BET BRD inhibitor scaffolds.

Acknowledgments

We thank Drs. Shameem Syeda and Sudhakar Jakkaraj for providing (−)-JQ1 and (+)-JQ1 and Jiewei Jiang for providing compound 2098312-12-8 for this study. We thank Brian Smith for providing the BRD4-T plasmid construct. We also thank Dr. Matthew Cuellar for performing LCMS purity analysis on both synthesized and commercially obtained compounds.

Glossary

ABBREVIATIONS

BD1

binding domain 1

BD2

binding domain 2

BET

bromodomain and extra-terminal domain

BRD

bromdomain

BRD2

bromodomain containing protein 2

BRD3

bromodomain containing protein 3

BRD4

bromodomain containing protein 4

BRDT

testes specific bromodomain containing protein

FP

fluorescence polarization

KAc

acetylated lysine

Supporting Information Available

The Supporting Information is available free of charge on the ACS Publications website at DOI: 10.1021/acsmedchemlett.8b00380.

  • Materials and methods; UV absorbance and fluorescence spectra of probes 16–18; saturation binding curves and a table of KD values of probes 16–18 for BRDT-1; saturation binding curves with probe 16 for BRDT-2, BRDT-T, BRD2-1, BRD2-2, BRD3-1, BRD3-2, BRD4-2, and BRD4-T; competitive displacement of probe 16 by 10 representative BET inhibitors against BRDT-T, BRD4-1, BRD4-2, BRD4-T, BRD3-1, BRD3-2, BRD2-1, and BRD2-2; references; NMR spectra (PDF)

Author Contributions

⊥ These authors contributed equally. All authors have given approval to the final version of the manuscript.

Financial support for this project is gratefully acknowledged from the NICHD (HHSN27520130001 and 1 U54 HD09354) and NSF-CAREER Award CHE-1352091.

The authors declare no competing financial interest.

Supplementary Material

ml8b00380_si_001.pdf (6.1MB, pdf)

References

  1. Kouzarides T. Chromatin modifications and their function. Cell 2007, 128, 693–705. 10.1016/j.cell.2007.02.005. [DOI] [PubMed] [Google Scholar]
  2. Zeng L.; Zhou M.-M. Bromdomain: an acetyl-lysine binding domain. FEBS Lett. 2002, 513, 124–128. 10.1016/S0014-5793(01)03309-9. [DOI] [PubMed] [Google Scholar]
  3. Muller S.; Filippakopoulos P.; Knapp S. Bromodomains as therapeutic targets. Expert Rev. Mol. Med. 2011, 13, e29. 10.1017/S1462399411001992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Jones M. H.; Numata M.; Shimane M. Identification and characterization of BRDT: a testis-specific gene related to the bromodomain genes RING3 and Drosophila fsh. Genomics 1997, 45, 529–534. 10.1006/geno.1997.5000. [DOI] [PubMed] [Google Scholar]
  5. Shang E.; Nickerson H. D.; Duancheng W.; Wang X.; Wolgemuth D. J. The first bromodomain of Brdt, a testis-specific member of the BET sub-family of double-bromodomain-containing proteins, is essential for male germ cell differentiation. Development 2007, 134, 3507–3515. 10.1242/dev.004481. [DOI] [PubMed] [Google Scholar]
  6. Miao Z.; Guan X.; Jiang J.; Georg G. I.. BRDT inhibitors for male contraceptive drug discovery: current status. In Targeting Protein–Protein Interactions by Small Molecules; Sheng C., Georg G. I., Eds.; Springer Nature Singapore Pte Ltd.: Singapore, 2018; pp 287–315. [Google Scholar]
  7. Shadrick W. R.; Slavish P. J.; Chai S. C.; Waddell B.; Connelly M.; Low J. A.; Tallant C.; Young B. M.; Bharatham N.; Knapp S.; Boyd V. A.; Morfouace M.; Roussel M. F.; Chen T.; Lee R. E.; Guy R. K.; Shelat A. A.; Potter P. M. Exploiting a water network to achieve-enthalpy-driven, bromodomain-selective BET inhibitors. Bioorg. Med. Chem. 2018, 26, 25–36. 10.1016/j.bmc.2017.10.042. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Urick A. K.; Hawk L. M. L.; Cassel M. K.; Mishra N. K.; Liu S.; Adhikari N.; Zhang W.; dos Santos C. O.; Hall J. L.; Pomerantz W. C. K. Dual screening of BPTF and Brd4 using protein-observed fluorine NMR uncovers new bromodomain probe molecules. ACS Chem. Biol. 2015, 10, 2246–2256. 10.1021/acschembio.5b00483. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Ayoub A. M.; Hawk L. M. L.; Herzig R. J.; Jiang J.; Wisniewski A. J.; Gee C. T.; Zhao P.; Zhu J.-Y.; Berndt N.; Offei-Addo N. K.; Scott T. G.; Qi J.; Bradner J. E.; Ward T. R.; Schönbrunn E.; Georg G. I.; Pomerantz W. C. K. BET Bromodomain inhibitors with one-step synthesis discovered from virtual screen. J. Med. Chem. 2017, 60, 4805–4817. 10.1021/acs.jmedchem.6b01336. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Chung C.; Coste H.; White J. H.; Mirguet O.; Wilde J.; Gosmini R. L.; Delves C.; Magny S. M.; Woodward R.; Hughes S. A.; Boursier E. V.; Flynn H.; Bouillot A. M.; Bamborough P.; Brusq J.-M. G.; Gellibert F. J.; Jones E. J.; Riou A. M.; Homes P.; Martin S. L.; Uings I. J.; Toum J.; Clément C. A.; Boullay A.-B.; Grimley R. L.; Blandel F. M.; Prinjha R. K.; Lee K.; Kirilovsky J.; Nicodeme E. Discovery and characterization of small molecule inhibitors of the BET family bromodomains. J. Med. Chem. 2011, 54, 3827–3838. 10.1021/jm200108t. [DOI] [PubMed] [Google Scholar]
  11. Zhao O.; Cao D.; Chen T.; Wang Y.; Miao Z.; Xu Y.; Chen W.; Wang X.; Li Y.; Du Z.; Xiong B.; Li J.; Xu C.; Zhang N.; He J.; Shen J. Fragment-based drug discovery of 2-thiazolidinones as inhibitors of the histone reader BRD4 bromodomain. J. Med. Chem. 2013, 56, 3833–3851. 10.1021/jm301793a. [DOI] [PubMed] [Google Scholar]
  12. Zhao L.; Wang Y.; Cao D.; Chen T.; Wang Q.; Li Y.; Xu Y.; Zhang N.; Wang X.; Chen D.; Chen L.; Chen Y. L.; Xia G.; Shi Z.; Liu Y. C.; Lin Y.; Miao Z.; Shen J.; Xiong B. Fragment-based drug discovery of 2-thiazolidinones as BRD4 inhibitors: 2. Structure-based optimization. J. Med. Chem. 2015, 58, 1281–1297. 10.1021/jm501504k. [DOI] [PubMed] [Google Scholar]
  13. Yu J.-I.; Chen T.-T.; Zhou C.; Lian F.-L.; Tang X.-L.; Wen Y.; Shen J.-K.; Xu Y.-C.; Xiong B.; Zhang N.-X. NMR-base platform for fragment-based lead discovery used in screening BRD4-targeted compounds. Acta Pharmacol. Sin. 2016, 37, 984–993. 10.1038/aps.2016.19. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Ember S. W.; Lambert Q. T.; Berndt N.; Gunawan S.; Ayaz M.; Tauro M.; Zhu J. Y.; Cranfill P. J.; Greninger P.; Lynch C. C.; Benes C. H.; Lawrence H. R.; Reuther G. W.; Lawrence N. J.; Schönbrunn E. Potent dual BET bromodo main-kinase inhibitors as value-added multitargeted chemical probes and cancer therapeutics. Mol. Cancer Ther. 2017, 16, 1054–1067. 10.1158/1535-7163.MCT-16-0568-T. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Cunha Dias de Rezende L.; Vaidergorn M. M.; Moraes J. C. B.; Emery F. D. Synthesis, photophysical properties and solvatochromism of meso-substituted tetramethyl BODIPY dyes. J. Fluoresc. 2014, 24, 257–266. 10.1007/s10895-013-1293-8. [DOI] [PubMed] [Google Scholar]
  16. Thivierge C.; Bandichhor R.; Burgess K. Spectral dispersion and water solubilization of BODIPY dyes via palladium-catalyzed C-H functionalization. Org. Lett. 2007, 9, 2135–2138. 10.1021/ol0706197. [DOI] [PubMed] [Google Scholar]
  17. Wu W. H.; Cui X. N.; Zhao J. Z. Hetero Bodipy-dimers as heavy atom-free triplet photosensitizers showing a long-lived triplet excited state for triplet-triplet annihilation upconversion. Chem. Commun. 2013, 49, 9009–9011. 10.1039/c3cc45470c. [DOI] [PubMed] [Google Scholar]
  18. Zhu S. L.; Bi J. H.; Vegesna G.; Zhang J. T.; Luo F. T.; Valenzano L.; Liu H. Y. Functionalization of BODIPY dyes at 2,6-positions through formyl groups. RSC Adv. 2013, 3, 4793–4800. 10.1039/c3ra22610g. [DOI] [Google Scholar]
  19. Jameson D. M.; Ross J. A. Fluorescence polarization/anisotropy in diagnostics and imaging. Chem. Rev. 2010, 110, 2685–2708. 10.1021/cr900267p. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Schönbrunn E.; Lawrence N. J.; Lawrence H. R.. Preparation of substituted pyrimidinediamines as potent dual BRD4-kinase inhibitors useful as cancer therapeutics. PCT Int. Appl. 2016, WO 2016022460 A1.
  21. Schönbrunn E.; Lawrence N. J.; Lawrence H. R.. 2,4-Diaminopyrimidines as BRD4 and kinase inhibitors as cancer therapeutics and their preparation. PCT Int. Appl. 2017, WO 2017066428 A1.
  22. Rousseau T.; Cravino A.; Bura T.; Ulrich G.; Ziessel R.; Roncali J. BODIPY derivatives as donor materials for bulk heterojunction solar cells. Chem. Commun. 2009, 1673–1675. 10.1039/b822770e. [DOI] [PubMed] [Google Scholar]
  23. Miller T. C.; Simon B.; Rybin V.; Grötsch H.; Crtet S.; Khochbin S.; Carlomagno T.; Müller C. W. A bromodomain-DNA interaction facilitates acetylation-dependent bivalent nucleosome recognition by the BET protein BRDT. Nat. Commun. 2016, 7, 13855. 10.1038/ncomms13855. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Nikolovska-Coleska Z.; Wang R.; Pan H.; Tomita Y.; Li P.; Roller P. P.; Krajewski K.; Saito N. G.; Stuckey J. A.; Wang S. Development and optimization of a binding assay for the XIAP BIR3 domain using fluorescence polarization. Anal. Biochem. 2004, 332, 261–273. 10.1016/j.ab.2004.05.055. [DOI] [PubMed] [Google Scholar]
  25. Bui M. H.; Lin X.; Albert D. H.; Li L.; Lam L. T.; Faivre E. J.; Warder S. E.; Huang X.; Wilcox D.; Donawho C. K.; Sheppard G. S.; Wang L.; Fidanze S.; Pratt J. K.; Liu D.; Hasvold L.; Uziel T.; Lu X.; Kohlhapp F.; Fang G.; Elmore S. W.; Rosenberg S. H.; McDaniel K. F.; Kati W. M.; Shen Y. Preclinical characterization of BET family bromodomain inhibitor ABBV-075 suggests combination therapeutic strategies. Cancer Res. 2017, 77, 2976–2989. 10.1158/0008-5472.CAN-16-1793. [DOI] [PubMed] [Google Scholar]
  26. Ember S. W. J.; Zhu J.-Y.; Olesen S. H.; Martin M. P.; Becker A.; Berndt N.; Georg G. I.; Schönbrunn E. Acetyl-lysine binding site of bromodomain-containing protein 4 (BRD4) interacts with diverse kinase inhibitors. ACS Chem. Biol. 2014, 9, 1160–1171. 10.1021/cb500072z. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Picaud S.; Leonards K.; Lambert J.-P.; Dovey O.; Wells C.; Fedorov O.; Monteiro O.; Fujisawa T.; Wang C.-Y.; Lingard H.; Tallant C.; Nikbin N.; Guetzoyan L.; Ingham R.; Ley S. V.; Brennan P.; Muller S.; Samsonova A.; Gingras A.-C.; Schwaller J.; Vassiliou G.; Knapp S.; Filippakopoulos P. Promiscuous targeting of bromodomains by bromosporine identifies BET proteins as master regulators of primary transcription response in leukemia. Sci. Adv. 2016, 2, e1600760. 10.1126/sciadv.1600760. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Philpott M.; Yang J.; Tumber T.; Fedorov O.; Uttarkar S.; Filippakopoulos P.; Picaud S.; Keates T.; Felletar I.; Ciulli A.; Knapp S.; Heightman T. D. Bromodomain-peptide displacement assays for interactome mapping and inhibitor discovery. Mol. BioSyst. 2011, 7, 2899–2908. 10.1039/c1mb05099k. [DOI] [PubMed] [Google Scholar]
  29. Li J.; Wang P.; Zhou B.; Shi J.; Liu J.; Li X.; Fan L.; Zheng Y.; Ouyang L. Development of 4,5-dihydro-benzodiazepinone derivatives as a new chemical series of BRD4 inhibitors. Eur. J. Med. Chem. 2016, 121, 294–299. 10.1016/j.ejmech.2016.05.057. [DOI] [PubMed] [Google Scholar]
  30. Filippakopoulos P.; Qi J.; Picaud S.; Shen Y.; Smith W. B.; Fedorov O.; Morse E. M.; Keates T.; Hickman T. T.; Felletar I.; Philpott M.; Munro S.; McKeown M. R.; Wang Y.; Christie A. L.; West N.; Cameron M. J.; Schwartz B.; Heightman T. D.; Thangue N. L.; French C. A.; Wiest O.; Kung A. L.; Knapp S.; Bradner J. E. Selective inhibition of BET bromodomains. Nature 2010, 468, 1067–1073. 10.1038/nature09504. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Zhang G.; Plotnikov A. N.; Rusinova E.; Shen T.; Morohashi K.; Joshua J.; Zeng L.; Mujtaba S.; Ohlmeyer M.; Zhou M.-M. Structure-guided design of potent diazobenzene inhibitors for the BET bromodomains. J. Med. Chem. 2013, 56, 9251–9264. 10.1021/jm401334s. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Picaud S.; Wells C.; Felletar I.; Brotherton D.; Martin S.; Savitsky P.; Diez-Dacal B.; Philpott M.; Bountra C.; Lingard H.; Fedorov O.; Müller S.; Brennan P. E.; Knapp S.; Filippakopoulos P. RVX-208, an inhibitor of BET transcriptional regulators with selectivity for the second bromodomain. Proc. Natl. Acad. Sci. U. S. A. 2013, 110, 19754–19759. 10.1073/pnas.1310658110. [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

ml8b00380_si_001.pdf (6.1MB, pdf)

Articles from ACS Medicinal Chemistry Letters are provided here courtesy of American Chemical Society

RESOURCES